The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Abstract
Objective. —To examine more closely the association between apolipoprotein E (APOE) genotype and Alzheimer disease (AD) by age and sex in populations of various ethnic and racial denominations. Data Sources. —Forty research teams contributed data onAPOEgenotype, sex, age at disease onset, and ethnic background for 5930 patients who met criteria for probable or definite AD and 8607 controls without dementia who were recruited from clinical, community, and brain bank sources. Main Outcome Measures. —Odds ratios (ORs) and 95% confidence intervals (Cls) for AD, adjusted for age and study and stratified by major ethnic group (Caucasian, African American, Hispanic, and Japanese) and source, were computed forAPOEgenotypes ∈2/∈2,∈2/∈3,∈2/∈4,∈3/∈4 and ∈4/∈4 relative to the ∈3/∈3 group. The influence of age and sex on the OR for each genotype was assessed using logistic regression procedures. Results. —Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes ∈2/∈4 (OR=2.6, 95% Cl=1.6-4.0), ∈3/∈4 (OR=3.2, 95% Cl=2.8-3.8), and ∈4/∈4 (OR=14.9, 95% CI=10.8-20.6); whereas, the ORs were decreased for people with genotypes ∈2/∈2 (OR=0.6, 95% Cl=0.2-2.0) and ∈2/∈3 (OR=0.6, 95% Cl=0.5-0.8). TheAPOE∈4-AD association was weaker among African Americans and Hispanics, but there was significant heterogeneity in ORs among studies of African Americans (P<.03). TheAPOE∈4—AD association in Japanese subjects was stronger than in Caucasian subjects (∈3/∈4: OR=5.6, 95% Cl=3.9-8.0; ∈4/∈4: OR=33.1, 95% Cl=13.6-80.5). The ∈2/∈3 genotype appears equally protective across ethnic groups. We also found that among Caucasians,APOEgenotype distributions are similar in groups of patients with AD whose diagnoses were determined clinically or by autopsy. In addition, we found that theAPOE∈4 effect is evident at all ages between 40 and 90 years but diminishes after age 70 years and that the risk of AD associated with a given genotype varies with sex. Conclusions. —TheAPOE∈4 allele represents a major risk factor for AD in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women. The association betweenAPOE∈4 and AD in African Americans requires clarification, and the attenuated effect ofAPOE∈4 in Hispanics should be investigated further.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The greatest risk factors for late-onset Alzheimer's are older age, 62,63 genetics 64,65 -especially the e4 form of the apolipoprotein E (APOE) gene -and having a family history of Alzheimer's.[66][67][68][69]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [65]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Also, previous studies of clinically and neuropathologically characterized cases and controls may have been too small to demonstrate that APOE2 homozygotes have an even lower OR than the relatively low-risk APOE2/3 group due to the paucity of APOE2 homozygotes, who comprise <1% of the general population1,4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Fourth, findings from our non-Hispanic White groups cannot yet be extended to other ethnic and racial groups4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“APOE is genetically linked to late-onset sporadic Alzheimer’s disease (LOAD), with APOE4 being a significant risk factor, APOE3 considered the “neutral” allele, and APOE2 exerting a protective role against LOAD [6, 7].”
In the citing paper
“In addition, APOE4 is linked to hypercholesterolemia and increased risk of cardiovascular disorders (CVD) [7, 41]”
In the citing paper
“Compared to ε3 homozygotes, individuals with one or two ε4 alleles harbor approximately 3 and 15 times increased risk, respectively”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“whereas carriers of the protective ε2 allele have an estimated 1.7 times decreased risk [1]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“Between 45% and 50% of AD patients carry at least one APOE4 allele compared to only 15% of age-matched healthy controls.5,11”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [11]
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“In humans, the APOE2/4 genotype confers an intermediate risk, higher than that of APOE3/3 but lower than APOE3/4 and APOE4/4 5,6 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“Population studies have demonstrated that the ε4 allele increases the risk of developing AD by either 3-fold (1 allele) or 12-fold (2 alleles) [6]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [6]
In the citing paper
“ApoE4, found in 65–80% of cases of sporadic and familial Alzheimer's disease, increases the occurrence of AD by ∼12 fold in two ɛ4 allele carriers, compared with those with no ɛ4 allele (Farrer et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Farrer et al., 1997
In the citing paper
“The APOE4 allele is a major genetic risk factor for late-onset AD and was previously shown to accelerate AD progression in humans and in mouse models 6-11 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [43]
In the citing paper
“Separately, clinical studies have reported that women APOE ε4 carriers had a higher risk of Alzheimer’s dementia than men carriers [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“Furthermore, a recent meta-analysis of 58000 participants showed that APOE ε3/ε4 women have the same increased odds of AD dementia as APOE ε3ε4 men have, in contrast to a previous meta-analysis which reported APOE ε4 women to carry a higher risk of Alzheimer’s dementia compared to APOE ε4 men [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“As APOE4 carriers make up 55–75% of AD cases17–20”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [18]
In the citing paper
“The initial intriguing observation that the APOEε4 allele increases AD risk differentially across races and ethnicities, with the greatest increase in risk seen in East Asian people, followed by white, then Black, then Hispanic people6, has now been confirmed by a larger meta-analysis using not only self-reported race and ethnicity but also global genetic ancestry to ascertain the biological basis”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“Rather, age and sex moderate the effects of the APOE genotype on AD risk so that the risk associated with the APOEε3/ε4 genotype is highest in women of ages 60–70 years (or 70–80 years according to ref. 6) but decreases in older women and equalizes to that of non-Hispanic White, Black and Hispanic men of the same age10.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“The APOE polymorphism is the most studied, successfully replicated, and well-established risk factor for AD where APOE*2 is the protective allele and APOE*4 is the risk allele as compared to APOE*3 [7–10].”
From Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk (2023) · cites this paper as [8]
In the citing paper
“The original association study implicating L28P with LOAD risk was carried out in a relatively small sample size.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“due to the complete linkage disequilibrium of L28P with APOE*4 (C112R)”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“it was associated with an elevated risk for AD [9]”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“In 1999, two groups independently identified a novel and rare missense mutation in the APOE gene [9, 10] in which the leucine residue is replaced by proline at codon 28 (L28P; rs769452).”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“with the East Asian population having a higher risk of AD associated with the APOE ε4 allele”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“while the effect of APOE ε4 is weaker in African American and Hispanic populations”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“The AD risk associated with common APOE alleles ε4 1 and ε2 2 is well established in European-ancestry individuals but varies considerably across other ancestries (Table 1). 3”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [3]
In the citing paper
“Among the AD susceptibility genes/loci identified to date, APOE remains the most significant genetic risk factor across populations.”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [8]
In the citing paper
“Although there is only about 20% of the population carrying the APOE ε4, this isoform is vastly enriched in AD patients with over 60% of symptomatic AD patients carrying at least one APOE ε4 allele”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Farrer et al 1997
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the dominant genetic risk factor for late-onset Alzheimer’s disease (AD).”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [5]
In the citing paper
“The genetic polymorphism of human apolipoprotein E (ApoE) has been shown to confer differential susceptibility to late-onset AD, which accounts for the majority of the AD cases (Farrer et al., 1997).”
From Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention (2018) · cites this paper as Farrer et al., 1997
In the citing paper
“occurs in approximately two-thirds of all cases [1–3]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer’s disease (AD)”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“In contrast, APOE3 is defined as risk-neutral while APOE2 represents the strongest genetic protective factor (Corder et al., 1994; Farrer et al., 1997; Reiman et al., 2020).”
From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Farrer et al., 1997
In the citing paper
“Since then, numerous studies have confirmed that possession of the ε4 allele is the strongest genetic risk factor for both AD and CAA, or a combination of both disorders (Bertram et al., 2007; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“However, in certain ethnic groups, the apoE ε4 allele seems to have either a weaker effect or no clear effect on AD (Farrer et al., 1997; Kalaria et al., 2008; Mayeux, 2003; Tang et al., 1998).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“Finally, it is important to note that the ε2 allele of apoE is associated with a lower risk for AD (Corder et al., 1994; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“APOE genotypes were in Hardy-Weinberg equilibrium in both cases and controls; their frequencies (Table 4) were similar to previous reports for the relevant age groups (44;47;48).”
From Association of ALS with head injury, cigarette smoking and APOE genotypes (2010) · cites this paper as [47]
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor for sporadic Alzheimer's Disease (AD).”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“An APOE ε4/ε4 individual of European ancestry has a sixteen-fold increase in AD risk and eighteen year earlier age at AD onset compared to a European ancestry individual carrying two copies of the more prevalent APOE ε3 allele 4 .”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“The global frequency of the human ε4 allele is 13.7%, and the frequency of ε4 carriers is increased to 40% in AD patients [452, 453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“Clinical incidence and average age of AD onset was found to be 91% at 68 years of age in ε4 homozygous carriers, 47% at 76 years of age in ε4 heterozygous carriers, and 20% at 84 years of age in non-ε4 individuals [453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“ApoE4 is present in roughly 20–25% of the human population, and apoE4 carriers account for 60–75% of AD cases in most clinical studies [11], highlighting the importance of apoE4 in AD pathogenesis.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“ApoE4 increases the risk and decreases the age of onset of AD in a gene dose dependent manner [4–11].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“the effect of APOEε4 has been reported to differ across ethnicities [58–61]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“the association between ε4 and disease is reported to be weaker among African-American and Hispanic individuals [58, 61, 62] and nonexistent among Nigerian individuals [63].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“APOEε2/APOEε4 individuals are still at increased risk for AD, suggesting the APOEε4 isoform exhibits some dominant effect over the APOEε2 isoform [58].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“Several studies have demonstrated APOE genotype has an exacerbated effect on disease risk in females [58]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Sorted by citations
Items 601–700 of 1,178
Genetic markers for diagnosis and pathogenesis of Alzheimer's disease
Kim, D., Yeo, S. H., Park, J.-M., Choi, J. Y., Lee, T.-H., Park, S. Y., Ock, M. S., Eo, J., Kim, H., & Cha, H. (2014) · Gene · doi:10.1016/j.gene.2014.05.031 · Cited by 133
How to Use an Article About Genetic Association
Attia, J., Ioannidis, J. P. A., Thakkinstian, A., McEvoy, M., Scott, R. J., Minelli, C., Thompson, J. R., Infante‐Rivard, C., & Guyatt, G. H. (2009) · JAMA · doi:10.1001/jama.2008.946 · Cited by 131
Pathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 137
The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease
Belkouch, M., Hachem, M., Elgot, A., Van, A. L., Picq, M., Guichardant, M., Lagarde, M., & Bernoud‐Hubac, N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.002 · Cited by 131
Georgakis, M. K., Kalogirou, E. Ι., Diamantaras, A.-A., Daskalopoulou, S. S., Munro, C. A., Lyketsos, C. G., Skalkidou, A., & Petridou, E. T. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.08.003 · Cited by 127
The current status of Alzheimer?s disease genetics: what do we tell the patients?
Bertram, L. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.11.018 · Cited by 132
Apolipoprotein E Genotype and Age-Related Myelin Breakdown in Healthy Individuals
Bartzokis, G., Lu, P. H., Geschwind, D. H., Edwards, N. J., Mintz, J., & Cummings, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.63 · Cited by 134
Fried, L. P. (2000) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a018031 · Cited by 126
“The role of genetic characteristics in age-related diseases has been dramatically demonstrated with the identification of the apolipoprotein E genotype as a major risk factor for Alzheimer's disease in persons over 60 years of age (75).”
BackgroundAssociation Between Apolipoprotein E 4 and Cognitive Decline in Elderly Adults
Packard, C. J., Westendorp, R. G. J., Stott, D. J., CASLAKE, M. J., Murray, H. M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., et al. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01415.x · Cited by 127
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 136
“…have a frequency in the population of 8.4% (ε2), 77.9% (ε3), and 13.7% (ε4), the frequency of the APOE ε4 variant (APOE4) is increased to at least 40% in sporadic AD patients (Farrer et al., 1997) making it the greatest known risk factor for sAD (Kanekiyo et al., 2014; Lambert et al., 2013).”
BackgroundInfluentialHypercholesterolaemia and vascular dementia
Appleton, J. P., Scutt, P., Sprigg, N., & Bath, P. M. (2017) · Clinical Science · doi:10.1042/cs20160382 · Cited by 129
Nakamura, T., Watanabe, A., Fujino, T., Hosono, T., & Michikawa, M. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-35 · Cited by 124
Barberger‐Gateau, P., Samieri, C., Féart, C., & Plourde, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391926 · Cited by 133
Chronic Traumatic Encephalopathy: Historical Origins and Current Perspective
Montenigro, P. H., Stein, T. D., Cantu, R. C., & Stern, R. A. (2015) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032814-112814 · Cited by 133
Brain Metabolic Alterations in Alzheimer’s Disease
Ardanaz, C. G., Ramírez, M. J., & Solas, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073785 · Cited by 135
Developmental and vascular risk factors for Alzheimer's disease
Borenstein, A. R., Wu, Y., Mortimer, J. A., Schellenberg, G. D., McCormick, W. C., Bowen, J. D., McCurry, S. M., & Larson, E. B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.04.010 · Cited by 127
Earlier Onset of Alzheimer Disease Symptoms in Latino Individuals Compared With Anglo Individuals
Clark, C. M., DeCarli, C. S., Mungas, D., Chui, H., Higdon, R., Nuñez, J., Fernandez, H., Negrón, M., Manly, J. J., Ferris, S. H., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.774 · Cited by 127
APOE-ε4 is associated with memory decline in cognitively impaired elderly
Dik, M. G., Jonker, C., Bouter, L. M., Geerlings, M. I., van Kamp, G. J., & Deeg, D. J. H. (2000) · Neurology · doi:10.1212/wnl.54.7.1492 · Cited by 128
Examination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128
APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba
Hendrie, H. C., Murrell, J., Baiyewu, O., Lane, K. A., Purnell, C., Ogunniyi, A., Unverzagt, F. W., Hall, K., Callahan, C. M., Saykin, A. J., et al. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214000167 · Cited by 123
“First published online 24 February 2014. populations (Farrer et al., 1997; Chuang et al., 2010; Ohara et al., 2011).”
ResultGenetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“Interestingly, the effect of APOE ε4 has been reported to differ across ethnicities (Farrer et al., 1997; Miyashita et al., 2013; Jun et al., 2017; Murrell et al., 2006), suggesting additional variants may interact with APOE to mediate its effect on AD risk.”
InfluentialABCA7 and Pathogenic Pathways of Alzheimer’s Disease
Aikawa, T., Holm, M., & Kanekiyo, T. (2018) · Brain Sciences · doi:10.3390/brainsci8020027 · Cited by 128
Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy
Yue, M., Hanna, A., Wilson, J., Roder, H. M., & Janus, C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.006 · Cited by 125
Genome-wide Association Studies in Alzheimer’s Disease: A Review
Tosto, G., & Reitz, C. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0381-0 · Cited by 131
Li, M., & Caeyenberghs, K. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.05.019 · Cited by 124
Kulick, E. R., Elkind, M. S. V., Boehme, A. K., Joyce, N. R., Schupf, N., Kaufman, J. D., Mayeux, R. P., Manly, J. J., & Wellenius, G. A. (2020) · Environment International · doi:10.1016/j.envint.2019.105440 · Cited by 122
The role of amyloid oligomers in neurodegenerative pathologies
Wells, C., Brennan, S. E., Keon, M., & Ooi, L. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.113 · Cited by 131
Jett, S., Malviya, N., Schelbaum, E., Jang, G., Jahan, E., Clancy, K., Hristov, H., Pahlajani, S. S., Niotis, K., Loeb‐Zeitlin, S., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.831807 · Cited by 124
Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain
Staessen, J. A., Richart, T., & Birkenhäger, W. H. (2007) · Hypertension · doi:10.1161/01.hyp.0000258151.00728.d8 · Cited by 128
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
Robson, K. J. H., Lehmann, D. J., Wimhurst, V. L. C., Livesey, K. J., Combrinck, M., Merryweather-Clarke, A. T., Warden, D. R., & Smith, A. D. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015552 · Cited by 120
Tang, M., Ryman, D. C., McDade, E., Jasielec, M. S., Buckles, V. D., Cairns, N. J., Fagan, A. M., Goate, A., Marcus, D. S., Xiong, C., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30229-0 · Cited by 121
Epistasis in sporadic Alzheimer's disease
Combarros, O., Cortina‐Borja, M., Smith, A. D., & Lehmann, D. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.027 · Cited by 128
Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease
Jagust, W. J., Landau, S. M., & Jack, C. R. (2021) · Neurology · doi:10.1212/wnl.0000000000011524 · Cited by 125
Genetic Case-Control Association Studies in Neuropsychiatry
Sullivan, P. F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.11.1015 · Cited by 121
Connectomic Intermediate Phenotypes for Psychiatric Disorders
Fornito, A., & Bullmore, E. T. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00032 · Cited by 121
Coram, M., Duan, Q., Hoffmann, T. J., Thornton, T. A., Knowles, J. W., Johnson, N. A., Ochs‐Balcom, H. M., Donlon, T. A., Martin, L. W., Eaton, C. B., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.025 · Cited by 123
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 130
“ApoE4 is nevertheless heavily enriched in AD patients, with 65–80% of AD patients carrying at least one Apo e4 allele [33], compared to worldwide frequency of about 14%.”
BackgroundGonzález, G., Martín, M., Cacho, Breñas, Arroyo, García‐Berrocal, Navajo, & González‐Buitrago (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00471.x · Cited by 120
The dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
Bojar, M. (2009) · Cited by 120
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 121
Eclipse of the Gene and the Return of Divination
Lock, M. M. (2005) · Current Anthropology · doi:10.1086/432452 · Cited by 128
The ACE gene and Alzheimer's disease susceptibility
Narain, Y., Yip, A., Murphy, T., Brayne, C., Easton, D., Evans, J. G., Xuereb, J., Cairns, N., Esiri, M., Furlong, R., et al. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.9.695 · Cited by 121
Nelson, M. R., Liu, P., Agrawal, A., Yip, O., Blumenfeld, J., Traglia, M., Kim, M. J., Koutsodendris, N., Rao, A., Grone, B., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01480-8 · Cited by 120
Role of Epigenetics in Alzheimer ‘S and Parkinson‘S Disease
Kwok, J. B. (2010) · Epigenomics · doi:10.2217/epi.10.43 · Cited by 124
Semick, S. A., Bharadwaj, R. A., Collado‐Torres, L., Tao, R., Shin, J. H., Deep‐Soboslay, A., Weiss, J. R., Weinberger, D. R., Hyde, T. M., Kleinman, J. E., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01966-5 · Cited by 121
Gómez‐Ramírez, J., Ávila‐Villanueva, M., & Fernández‐Blázquez, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77296-4 · Cited by 118
Biomarkers of neurodegenerative disorders: How good are they?
Rachakonda, V., Pan, T. H., & Le, W. D. (2004) · Cell Research · doi:10.1038/sj.cr.7290235 · Cited by 119
Amalgam studies: Disregarding basic principles of mercury toxicity
Mutter, J., Naumann, J., Sadaghiani, C., et al. (2004) · International Journal of Hygiene and Environmental Health · doi:10.1078/1438-4639-00305 · Cited by 118
Association of ALS with head injury, cigarette smoking and APOE genotypes
Schmidt, S., Kwee, L. C., Allen, K. D., & Oddone, E. Z. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.01.011 · Cited by 117
Prediction of Alzheimer's Disease Progression with Multi-Information Generative Adversarial Network
Zhao, Y., Ma, B., Jiang, P., Zeng, D., Wang, X., & Li, S. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3006925 · Cited by 125
Preventing dementia? Interventional approaches in mild cognitive impairment
Lissek, V. J., & Boris Suchan, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.022 · Cited by 127
Selenium-enriched plant foods: Selenium accumulation, speciation, and health functionality
Tangjaidee, P., Swedlund, P. J., Xiang, J., Yin, H., & Quek, S. Y. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.962312 · Cited by 124
Wiltfang, J., Lewczuk, P., Riederer, P. F., Grünblatt, E., Hock, C., Scheltens, P., Hampel, H. J., Vanderstichele, H., Iqbal, K., Galasko, D. R., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029786 · Cited by 120
Association studies of bipolar disorder
Craddock, N. J., Dave, S., & Greening, J. (2001) · Bipolar Disorders · doi:10.1034/j.1399-5618.2001.30604.x · Cited by 118
Dementia with Lewy Bodies. A Distinct Non‐Alzheimer Dementia Syndrome?
Ince, P. G., Perry, E. K., & Morris, C. M. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00156.x · Cited by 116
Luck, T., Riedel-Heller, S. G., Luppa, M., Wiese, B., Wollny, A., Wagner, M., Bickel, H., Weyerer, S. B., Pentzek, M., Haller, F., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01481.x · Cited by 118
Contribution of APOE promoter polymorphisms to Alzheimer’s disease risk
Lambert, J., Goumidi, L., Myllykangas, L., Ellis, C., Wang, J. C., Bullido, M. J., Harris, J. M., Artiga, M. J., Hernandez, D. G., Kwon, J. M., et al. (2002) · Neurology · doi:10.1212/wnl.59.1.59 · Cited by 114
Scott, W. K., Grubber, J. M., Conneally, P. M., Small, G. W., Hulette, C. M., Rosenberg, C. K., Saunders, A. M., Roses, A. D., Haines, J. L., & Pericak‐Vance, M. A. (2000) · The American Journal of Human Genetics · doi:10.1086/302828 · Cited by 114
“50% of the risk of AD attributed to genetics, indicating that additional AD loci exist (Farrer et al. 1997).”
BackgroundAPOE genotype and sex affect microglial interactions with plaques in Alzheimer’s disease mice
Stephen, T. L., Cacciottolo, M., Balu, D., Morgan, T. E., LaDu, M. J., Finch, C. E., & Pike, C. J. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0729-z · Cited by 115
Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes
Panza, F., Capurso, C. A., D’Introno, A., Colacicco, A. M., Frisardi, V., Lorusso, M., Santamato, A., Seripa, D., Pilotto, A., Scafato, E., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1009 · Cited by 117
Gemmati, D., Varani, K., Bramanti, B., Piva, R., Bonaccorsi, G., Trentini, A., Manfrinato, M. C., Tisato, V., Carè, A., & Bellini, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010296 · Cited by 120
Deters, K., Napolioni, V., Sperling, R. A., Greicius, M. D., Mayeux, R. P., Hohman, T. J., & Mormino, E. C. (2021) · Neurology · doi:10.1212/wnl.0000000000011599 · Cited by 118
Taubes, A., Nova, P., Zalocusky, K. A., Kosti, I., Bicak, M., Zilberter, M. Y., Hao, Y., Yoon, S. Y., Oskotsky, T., Pineda, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00122-7 · Cited by 118
Genetics of human prefrontal function
Winterer, G., & Goldman, D. A. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00205-4 · Cited by 119
Mitochondrial dysfunction and Alzheimer's disease
Maruszak, A., & Żekanowski, C. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.004 · Cited by 124
Heffernan, A. L., Chidgey, C., Peng, P., Masters, C. L., & Roberts, B. R. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0804-x · Cited by 113
“Similar ethnic differences of APOE ε4 allele frequency to those reported by Farrer et al .”
BackgroundResultInfluentialOpen science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease
Tremblay‐Mercier, J., Madjar, C., Das, S., Binette, A. P., Dyke, S. O. M., Etienne, P. E., Lafaille‐Magnan, M., Remz, J., Bellec, P., Collins, D. L., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102733 · Cited by 115
Roberts, J. S., Barber, M., Brown, T., Cupples, L. A., Farrer, L. A., LaRusse, S., Post, S. G., Quaid, K. A., Ravdin, L., Relkin, N. R., et al. (2004) · Genetics in Medicine · doi:10.1097/01.gim.0000132688.55591.77 · Cited by 113
Self-citationThe apolipoprotein E gene, attention, and brain function.
Parasuraman, R., Greenwood, P. M., & Sunderland, T. (2002) · Neuropsychology · doi:10.1037//0894-4105.16.2.254 · Cited by 134
“In contrast, the 2 allele appears to confer a protective effect with regard to AD risk (Corder et al., 1994; Farrer et al., 1997; Lippa et al., 1997).”
BackgroundBrodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Association Between Apolipoprotein E Genotype and Alzheimer Disease in African American Subjects
Graff‐Radford, N. R., Green, R. C., Go, R. C. P., Hutton, M. L., Edeki, T. I., Bachman, D., Adamson, J. L., Griffith, P. A., Willis, F. B., Williams, M. P., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.4.594 · Cited by 109
Self-citationGenetic factors associated with longevity: A review of recent findings
Shadyab, A. H., & LaCroix, A. Z. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.10.005 · Cited by 112
Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease
Salloway, S., Gur, T., Berzin, T., Zipser, B., Correia, S., Hovanesian, V, Fallon, J., Kuo-Leblanc, V, Glass, D., Hulette, C., et al. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00288-5 · Cited by 113
Roses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 109
Engelborghs, S., Sleegers, K., Cras, P. P., Brouwers, N., Serneels, S., Leenheir, E. D., Martin, J. J., Vanmechelen, E., Broeckhoven, C. V., & Deyn, P. P. D. (2007) · Brain · doi:10.1093/brain/awm136 · Cited by 114
“Although the e4 allele of APOE is a well-established risk factor for AD (Farrer et al., 1997), studies on possible associations between CSF biomarker levels and e4 produced conflicting results.”
ResultAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Johnson, S. C., La Rue, A., Hermann, B. P., Xu, G., Koscik, R. L., Jonaitis, E. M., Bendlin, B. B., Hogan, K. J., Roses, A. D., Saunders, A. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.012 · Cited by 112
ApoE and Neurodegenerative Diseases in Aging
Yin, Y., & Wang, Z. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_5 · Cited by 111
Do Microglial Sex Differences Contribute to Sex Differences in Neurodegenerative Diseases?
Kodama, L., & Gan, L. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.001 · Cited by 118
Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics
Blue, E., Horimoto, A. R. V. R., Mukherjee, S., Wijsman, E. M., & Thornton, T. A. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.016 · Cited by 113
Belloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., Greicius, M. D., & Initiative, F. T. A. D. N. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0414 · Cited by 110
Harwood, D. G., Kalechstein, A. D., Barker, W., Strauman, S., George‐Hyslop, P. S., Iglesias, C., Loewenstein, D., & Duara, R. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2372 · Cited by 112
“For example, the e4 allele of the apolipoprotein gene located on chromosome 19 (APOE) is overrepresented in AD cases compared to age-matched controls (Farrer et al., 1997).”
BackgroundClinical Features of Rapidly Progressive Alzheimer’s Disease
Schmidt, C., Redyk, K., Meißner, B., Krack, L. A., von Ahsen, N., Roeber, S., Kretzschmar, H. A., & Zerr, I. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000278692 · Cited by 112
Qiu, C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.021493 · Cited by 115
Reduction in DHA transport to the brain of mice expressing human APOE 4 compared to APOE 2
Vandal, M., Alata, W., Tremblay, C., Rioux‐Perreault, C., Salem, N., Calon, F., & Plourde, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12640 · Cited by 124
Omega-3 fatty acids and cognitive function
Welty, F. K. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000862 · Cited by 121
The Dawning Era of Personalized Medicine Exposes a Gap in Medical Education
Salari, K. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000138 · Cited by 111
Sex-specific genetic predictors of Alzheimer’s disease biomarkers
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetics Consortium (ADGC), Dumitrescu, L., Barnes, L. L., Thambisetty, M., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1881-4 · Cited by 110
Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils
Hatters, D. M., Zhong, N., Rutenber, E., & Weisgraber, K. H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.080 · Cited by 105
Menopause, obesity and inflammation: interactive risk factors for Alzheimer’s disease
Christensen, A., & Pike, C. J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00130 · Cited by 112
“Further, the ApoE4 genotype may increase the risk of AD more in females than males (Farrer et al., 1997; Bretsky et al., 1999).”
BackgroundNeuronutrition and Alzheimer's Disease
Ramesh, B. N., Rao, T. S., Prakasam, A., Sambamurti, K., & Rao, K. S. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1312 · Cited by 113
Exercise and the Aging Brain: Considerations for Sex Differences
Barha, C. K., & Liu-Ambrose, T. Y. L. (2018) · Brain Plasticity · doi:10.3233/bpl-180067 · Cited by 126
Education, Cognitive Test Scores, and Black‐White Differences in Dementia Risk
Shadlen, M., Siscovick, D. S., Fitzpatrick, A. L., Dulberg, C. S., Kuller, L. H., & Jackson, S. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00747.x · Cited by 110
Bartzokis, G., Lu, P. H., Geschwind, D. H., Tingus, K., Huang, D., Mendez, M. F., Edwards, N., & Mintz, J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.024 · Cited by 109
APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging
Bunce, D. J., Fratiglioni, L., Small, B. J., Winblad, B. G., & Bäckman, L. (2004) · Neurology · doi:10.1212/01.wnl.0000137041.86153.42 · Cited by 111
Frequency of Alzheimer's Disease and Other Dementias in a Community Outreach Sample of Hispanics
Fitten, L. J., Ortiz, F., & Pontón, M. O. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49257.x · Cited by 110
Metadata
- Authors
- Farrer, L. A.
- Corresponding author
- Farrer, Lindsay A.
- ORCID
- Farrer, Lindsay A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-10-22
- Volume
- 278
- Issue
- 16
- Pages
- 1349
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W7028228764
- Cited by
- 124
- References
- 0
- Citations by year
- 2026: 16 · 2025: 8 · 2024: 6 · 2023: 12 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, genetic risk, age of onset, sex differences, ethnic differences, African Americans, Hispanic population, Japanese population, genetic heterogeneity, dementia risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
